JPRN-UMIN000040696已完成2 期
Phase II trial of anti-PD-1 therapy after anti-PD-L1 therapy in patients with unresectable locally advanced or advanced non-small-cell lung cancer - Phase II trial of anti-PD-1 therapy after anti-PD-L1 therapy
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 75
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Subjects with an active infection requiring systemic treatment. History of the treatment of anti PD-L1, anti-CTLA-4 antibody or drugs of effect to T cell. Subjects with an active Gastrointestinal ulcer. Subjects with past or present history of interstitial lung disease diagnosed by clinical or imaging findings. History of allergy or hypersensitivity to study drug components. Subjects with an active or refractory autoimmune disease. Subjects with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll. Known history of testing positive for HIV antibody, HBs antigen, HCV antibody and HCV-RNA. If HBs antibody or HBc antibody was positive, subjects testing negative for HBV-DNA is permitted to enroll. Subjects who are or may be pregnant, or are breast-feeding. Subjects with psychiatric illness.
研究者
相似试验
已完成
2 期
A Phase II trial of immunotherapy with an anti-PD-1 antibody in advanced / relapsed, Platinum - resistant Ovarian Cancerovarian cancerJPRN-UMIN000005714Department of Gynecology and Obstetrics, Kyoto University Hospital20
进行中（未招募）
1 期
udwigEUCTR2015-005298-19-GBudwig Institute for Cancer Research Ltd.75
招募中
2 期
Atezolizumab After Chemo-radiotherapy for muscle-invasive bladder cancer Patients Not Eligible for Radical Cystectomy2024-512002-26-00Unicancer77
招募中
2 期
A phase II open-label study with the anti-PD-L1 Atezolizumab monoclonal antibody in combination with Bevacizumab in patients with advanced chemotherapy resistant colorectal cancer and MSI-like molecular signaturebowlecancercolorectal carcinoma10017991NL-OMON49178Vall D'Hebron Institute of Oncology (VHIO)12
进行中（未招募）
1 期
Atezolizumab in combination with Beva in advanced CRC with MSI-like molecular signatureColorectal carcinomaMedDRA version: 20.0Level: PTClassification code 10061451Term: Colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-002001-19-ESVHIO58